近日,诺诚健华宣布与Zenas就三款自免管线达成授权许可合作,Zenas将向诺诚健华支付达1亿美元的首付款和近期里程碑付款,以及向诺诚健华发行达700万股Zenas普通股股票,加上其他达成临床开发、注册和商业化里程碑的付款,总交易金额超过20亿美元。创新药出海向来是行业关注的焦点。2025年5月,随着三生制药的SSGJ-707成功授权辉瑞,高达12.5亿美金的首付款,以及潜在60.5亿美金的总交易...
Source Link近日,诺诚健华宣布与Zenas就三款自免管线达成授权许可合作,Zenas将向诺诚健华支付达1亿美元的首付款和近期里程碑付款,以及向诺诚健华发行达700万股Zenas普通股股票,加上其他达成临床开发、注册和商业化里程碑的付款,总交易金额超过20亿美元。创新药出海向来是行业关注的焦点。2025年5月,随着三生制药的SSGJ-707成功授权辉瑞,高达12.5亿美金的首付款,以及潜在60.5亿美金的总交易...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.